Our Pricing

Affordable Wegovy UK - All Doses In Stock & Ready to Ship

Published on: June 03, 2026

Finding an affordable Wegovy UK online pharmacy with consistent stock availability can be challenging during ongoing supply constraints. At Cured Pharmacy, we maintain all Wegovy doses in stock at £79.00, with transparent upfront pricing, free clinical consultations under 3 minutes, and discreet next-day delivery across the UK.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to regulate appetite and food intake [1]. By activating GLP-1 receptors in the brain, Wegovy reduces hunger signals and increases feelings of fullness after meals, helping patients consume fewer calories naturally.

In the landmark STEP 1 clinical trial, participants using Wegovy 2.4mg weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. These results led to Wegovy's MHRA approval in the UK as the first semaglutide treatment specifically licensed for chronic weight management in adults with a BMI of 30 or above, or 27 or above with weight-related health conditions [2].

Unlike oral weight loss medications, Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen. The treatment follows a gradual dose escalation schedule over 16-20 weeks, starting at 0.25mg and increasing to the maintenance dose of 2.4mg weekly, which minimises gastrointestinal side effects during the adjustment period [3].

Wegovy Dosing Schedule and What to Expect

Your UK prescriber will start you on the lowest Wegovy dose and gradually increase it according to the MHRA-approved titration schedule. This stepwise approach allows your body to adapt to the medication whilst reducing the likelihood of nausea and other gastrointestinal symptoms.

The standard Wegovy dosing schedule progresses as follows: 0.25mg weekly for 4 weeks, 0.5mg weekly for 4 weeks, 1mg weekly for 4 weeks, 1.7mg weekly for 4 weeks, and finally the maintenance dose of 2.4mg weekly [3]. If you experience persistent side effects at any stage, your prescriber may extend that dose level for an additional 4 weeks before continuing the escalation.

What Results Can You Expect?

Clinical trial data shows that most weight loss occurs during the first 60 weeks of treatment, with patients typically noticing reduced appetite within the first few weeks [1]. In the STEP programme trials, 86% of participants achieved at least 5% body weight reduction, whilst 69% achieved 10% or greater reduction at 68 weeks [1]. Individual results vary based on adherence to the medication, dietary modifications, and physical activity levels, which is why Wegovy is prescribed alongside a reduced-calorie diet and increased physical activity programme.

Why Choose Cured Pharmacy for Affordable Wegovy UK

As a UK-registered online pharmacy (GPhC Registration Number 9012511) under superintendent pharmacist Tarun Kumar (GPhC 2233073), Cured Pharmacy dispenses only genuine UK-licensed Wegovy pens sourced directly from authorised wholesalers. Every pen carries full UK regulatory approval and batch traceability.

Our transparent pricing model shows you the exact cost before your consultation begins — £79.00 for Wegovy, with no hidden fees or subscription requirements. After completing your free online clinical assessment, a UK-registered prescriber reviews your medical history, current medications, and weight loss goals to determine if Wegovy is suitable for you. If approved, we dispense your prescription and arrange discreet next-day delivery to your preferred UK address.

We maintain comprehensive stock levels across all Wegovy doses, including the starter packs and maintenance doses, ensuring continuity of your treatment without interruption. Our clinical team is available at (+44) 116 4646009 if you have questions about your prescription or need support during your weight loss journey.

Our Commitment to Patient Safety

Every Wegovy prescription at Cured Pharmacy undergoes thorough clinical review by UK-registered prescribers who assess contraindications, drug interactions, and individual suitability. We do not approve prescriptions for patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or those currently pregnant or breastfeeding, in accordance with MHRA prescribing guidelines [2].

Wegovy Side Effects and How to Manage Them

The most common side effects reported in clinical trials were gastrointestinal symptoms, including nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects typically occur during dose escalation and diminish as your body adjusts to the medication over several weeks.

To minimise nausea, eat smaller, more frequent meals rather than large portions, avoid high-fat or fried foods, and stay well-hydrated throughout the day. Injecting Wegovy at the same time each week, preferably in the evening after your main meal, can also help reduce digestive discomfort. If side effects persist or become severe, contact your prescriber — they may recommend extending your current dose level before increasing further.

Serious but rare side effects include pancreatitis (inflammation of the pancreas), gallbladder problems, and hypoglycaemia if used alongside certain diabetes medications [2]. Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction such as difficulty breathing or facial swelling.

Who Can Use Wegovy: Eligibility Criteria

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease [2]. Your UK prescriber will calculate your BMI during the consultation and assess whether you meet these clinical criteria.

The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as GLP-1 receptor agonists have been associated with thyroid C-cell tumours in animal studies [2]. Wegovy should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment and for 2 months after discontinuation.

When to Avoid Wegovy

Your prescriber will not approve Wegovy if you have severe gastrointestinal disease such as gastroparesis, inflammatory bowel disease, or a history of pancreatitis. Patients with diabetic retinopathy should be monitored closely, as rapid weight loss may temporarily worsen this condition [3]. Always disclose your complete medical history and current medications during your consultation to ensure safe prescribing.

Affordable Wegovy UK: Maintaining Your Treatment Long-Term

Weight management with Wegovy is a long-term commitment that works best when combined with sustainable lifestyle modifications. Clinical trials show that discontinuing the medication typically leads to weight regain, which is why most patients continue treatment for 12 months or longer, subject to ongoing clinical review [4].

At Cured Pharmacy, we support treatment continuity through reliable stock availability and straightforward repeat prescription processes. Once you've completed your initial consultation and titration schedule, reordering your maintenance dose takes under 2 minutes through your patient account. Our UK clinical team reviews each repeat prescription to monitor your progress and ensure the treatment remains appropriate for your health status.

The cost-effectiveness of Wegovy improves with consistent use over time. At £79.00 per month on the maintenance dose, combined with the average 14.9% body weight reduction observed in clinical trials [1], many patients find the investment worthwhile compared to the long-term health costs associated with obesity-related conditions. Your prescriber will schedule regular reviews to assess your response to treatment and determine optimal treatment duration based on your individual weight loss goals and overall health outcomes.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://products.mhra.gov.uk/ [accessed 13 August 2026]
3. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity.